

### Optimization of the Tango™ CCR1-bla U2OS Cell Line

Tango™ CCR1-bla U2OS DA Assay Kit

Tango™ CCR1-bla U2OS cells

Catalog Numbers - K1793 and K1787

### **Cell Line Descriptions**

Tango™ CCR1-bla U2OS DA (Division Arrested) cells and Tango™ CCR1-bla U2OS cells contain the human Chemokine (C-C Motif) Receptor 1 (CCR1) linked to a TEV protease site and a Gal4-VP16 transcription factor stably integrated into the Tango™ GPCR-bla U2OS parental cell line. This parental cell line stably expresses a beta-arrestin/TEV protease fusion protein and the beta-lactamase reporter gene under the control of a UAS response element. Division Arrested (DA) cells are available as an Assay Kit, which includes cells and sufficient substrate to analyze 1 x 384-well plate.

DA cells are irreversibly division arrested using a low-dose treatment of Mitomycin C, and have no apparent toxicity or change in cellular signal transduction. Both the Tango<sup>TM</sup> CCR1-bla U2OS cells and the Tango<sup>TM</sup> CCR1-bla U2OS DA cells have been functionally validated for Z' factor and EC<sub>50</sub> concentrations of MIP-1a (Figure 1). In addition, Tango<sup>TM</sup> CCR1-bla U2OS cells have been tested for assay performance under variable conditions.

NA: 800-955-6288 or INTL: 760-603-7200 Select option 3, ext. 40266 Email: <a href="mailto:drugdiscoverytech@invitrogen.com">drugdiscoverytech@invitrogen.com</a>



# **Validation Summary**

Testing and validation of this assay was evaluated in a 384-well format using LiveBLAzer™-FRET B/G Substrate.

# 1. MIP-1a dose response under optimized conditions


	<u>DA cells</u>	<u>Dividing Cells</u>
EC <sub>50</sub>	3.2 nM	2.8 nM
Z'-factor	0.83	0.72
Recommended cell no. /well		= 10,000
Recommended Stim. Time		= 5 hrs
Max. [Stimulation]		= 641  nM

## 2. Antagonist dose response

**vMIP II**  $IC_{50}$  = 78 nM

# **Primary Agonist Dose Response**


Figure 1 — Tango™ CCR1-bla U2OS cells and Tango™ CCR1-bla U2OS DA cells dose response to MIP-1a under optimized conditions



Tango™ CCR1-bla U2OS cells and Tango™ CCR1-bla U2OS DA cells (10,000 cells/well) were plated in a 384-well format and incubated for 16-20 hours. Cells were stimulated with a dilution series of MIP-1a (Biosource (IVGN) PHC1105) in the presence of 0.1% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm were obtained using a standard fluorescence plate reader and % Activation plotted for each replicate against the concentrations of MIP-1a.

# **Antagonist Dose Response**

Figure 3 — Tango™ CCR1-bla U2OS cells dose response to vMIP II



Tango™ CCR1-bla U2OS cells (10,000 cells/well) were plated in a 384-well format and incubated for 16-20 hours. Cells were exposed to vMIP II (R&D systems 601-VB) for 30 min. and then stimulated with an EC80 concentration of MIP-1a (Biosource (IVGN) PHC1105) in the presence of 0.1% DMSO for 5 hours. Cells were then loaded with LiveBLAzer™-FRET B/G Substrate for 2 hours. Fluorescence emission values at 460 nm and 530 nm for the various substrate loading times were obtained using a standard fluorescence plate reader and the % Inhibition plotted against the indicated concentrations of vMIP II.